

Certificate of Analysis for NR-51538

Pseudomonas aeruginosa, Strain MRSN 2108

Catalog No. NR-51538

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 2108 was isolated in 2011 from a human tissue sample as part of a surveillance program in the United States. *P. aeruginosa*, strain MRSN 2108 was deposited as sensitive to amikacin, gentamicin and tobramycin and resistant to aztreonam, meropenem, imipenem, levofloxacin and ciprofloxacin with intermediate resistance to piperacillin/tazobactam, cefepime, and ceftazidime.

Lot: 70024948¹ Manufacturing Date: 10MAY2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphologies ^{2,3}	Report results	Colony type 1: Circular, low convex, entire and smooth (Figure 1) Colony type 2: Irregular, flat, undulate, opaque and green (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK® 2 (GN card)	P. aeruginosa (≥ 89%)	P. aeruginosa (≥ 97%)
Antibiotic Susceptibility Profile ^{4,5} VITEK® (AST-GN81 Card)	Donat worth	Decistant (200 confeel)
Ampicillin	Report results	Resistant (≥ 32 μg/mL)
Amoxicillin/clavulanic acid	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/tazobactam	Intermediate	Intermediate (64 µg/mL)
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Intermediate	Variable (16-32 μg/mL)
Ceftriaxone	Report results	Resistant (≥ 64 µg/mL)
Cefepime	Intermediate	Intermediate (16 µg/mL)
Meropenem	Resistant	Resistant (≥ 16 μg/mL)
Amikacin	Sensitive	Sensitive (≤ 2 μg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 μg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Ciprofloxacin	Resistant	Variable (2-4 μg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 μg/mL)
Trimethoprim/sulfamethoxazole	Report results	≥ 320 µg/mL ⁶
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1430 base pairs)	≥ 99% sequence identity to P. aeruginosa, strain MRSN 2108 (GenBank: RXUS01000042.1)	100% sequence identity to P. aeruginosa, strain MRSN 2108 (GenBank: RXUS01000042.1)
Purity (post-freeze) ^{7,8}	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze) ²	Growth	Growth

¹NR-51538 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

NR-51538 70024948 24JAN2020

²1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

³Two colony types were observed. Plating of the individual colony types showed that they reverted to the mixed colony type. VITEK® GN card analysis identified cells from both colony types as *P. aeruginosa*.


⁴Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)



Certificate of Analysis for NR-51538

SUPPORTING INFECTIOUS DISEASE RESEARCH

Figure 1: Colony Morphologies



/Heather Couch/

Heather Couch 24 JAN 2020

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

⁵Antibiotic susceptibility testing was performed for each colony type and interpretations are identical except where indicated.

⁶Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa*." <u>Antimicrob. Agents Chemother.</u> 40 (1996): 2288-2290. PubMed: 9036831.

Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with and without 5% CO₂ on Tryptic Soy agar.

⁸Two colony types were observed after 1 day of growth in an aerobic atmosphere with 5% CO₂. Plating of the individual colony types showed that they did not revert to the mixed colony type. VITEK® GN card analysis identified cells from both colony types as *P. aeruginosa*.